NASDAQ:NVCN Neovasc Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neovasc Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.20 +0.03 (+1.38 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.13Now: $2.20▼$2.2050-Day Range$2.08MA: $2.27▼$2.8052-Week Range$1.24Now: $2.20▼$8.65Volume116,814 shsAverage Volume346,404 shsMarket Capitalization$49.82 millionP/E RatioN/ADividend YieldN/ABeta2.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingNeovasc has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, Neovasc has a forecasted upside of 229.5% from its current price of $2.20.Amount of Analyst CoverageNeovasc has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesNeovasc has received 388 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeovasc has received 307 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeovasc has received 55.83% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote “Outperform” if you believe NVCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeovasc does not currently pay a dividend.Dividend GrowthNeovasc does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neovasc insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 17.79% of the stock of Neovasc is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neovasc are expected to grow in the coming year, from ($1.83) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neovasc is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neovasc is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCN Previous Symbol CUSIPN/A CIK1399708 Webwww.neovasc.com Phone604-248-4138Debt Debt-to-Equity RatioN/A Current Ratio1.67 Quick Ratio1.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.09 million Price / Sales23.84 Cash FlowN/A Price / Cash FlowN/A Book Value($1.46) per share Price / Book-1.51Profitability EPS (Most Recent Fiscal Year)($5.05) Net Income$-35,130,000.00 Net Margins-1,729.99% Return on EquityN/A Return on Assets-230.94%Miscellaneous Employees98 Outstanding Shares22,647,000Market Cap$49.82 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $2.20 +0.03 (+1.38 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NVCN News and Ratings via Email Sign-up to receive the latest news and ratings for NVCN and its competitors with MarketBeat's FREE daily newsletter. Neovasc (NASDAQ:NVCN) Frequently Asked Questions How has Neovasc's stock price been impacted by COVID-19 (Coronavirus)? Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVCN shares have decreased by 0.5% and is now trading at $2.20. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Neovasc? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neovasc. When is Neovasc's next earnings date? Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Neovasc. How were Neovasc's earnings last quarter? Neovasc Inc (NASDAQ:NVCN) issued its quarterly earnings data on Thursday, August, 6th. The medical equipment provider reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.22. The medical equipment provider had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.30 million. View Neovasc's earnings history. When did Neovasc's stock split? How did Neovasc's stock split work? Neovasc shares reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split. What guidance has Neovasc issued on next quarter's earnings? Neovasc updated its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $295K - 295K. What price target have analysts set for NVCN? 4 equities research analysts have issued 1-year target prices for Neovasc's stock. Their forecasts range from $3.00 to $15.00. On average, they expect Neovasc's share price to reach $7.25 in the next year. This suggests a possible upside of 229.5% from the stock's current price. View analysts' price targets for Neovasc. Are investors shorting Neovasc? Neovasc saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 73,000 shares, a decrease of 50.7% from the August 15th total of 148,100 shares. Based on an average trading volume of 432,700 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.4% of the shares of the company are short sold. View Neovasc's Short Interest. Who are some of Neovasc's key competitors? Some companies that are related to Neovasc include Liquidia Technologies (LQDA), T2 Biosystems (TTOO), Apyx Medical (APYX), Soliton (SOLY), DarioHealth (DRIO), Lyra Therapeutics (LYRA), Pro-Dex (PDEX), BeyondAirInc . (XAIR), PAVmed (PAVM), Restoration Robotics (HAIR), Venus Concept (VERO), ClearPoint Neuro (CLPT), Spectral Medical (EDTXF), Neuronetics (STIM) and SANUWAVE Health (SNWV). View all competitors. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), 22nd Century Group (XXII), Heat Biologics (HTBX), Protalix Biotherapeutics (PLX), TOP SHIPS (TOPS) and Amarin (AMRN). Who are Neovasc's key executives? Neovasc's management team includes the following people: Mr. Fredericus A. Colen, Pres & CEO (Age 66)Mr. Christopher Clark B.A., C.A., BA (Honours), PgD, CA, CFO & Corp. Sec. (Age 47) What is Neovasc's stock symbol? Neovasc trades on the NASDAQ under the ticker symbol "NVCN." Who are Neovasc's major shareholders? Neovasc's stock is owned by many different retail and institutional investors. Top institutional investors include Hudson Bay Capital Management LP (5.68%), Sabby Management LLC (2.93%), Two Sigma Advisers LP (0.29%), Wedbush Securities Inc. (0.40%) and Bank of America Corp DE (0.18%). Which major investors are buying Neovasc stock? NVCN stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Sabby Management LLC, Wedbush Securities Inc., Two Sigma Advisers LP, and Bank of America Corp DE. How do I buy shares of Neovasc? Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neovasc's stock price today? One share of NVCN stock can currently be purchased for approximately $2.20. How big of a company is Neovasc? Neovasc has a market capitalization of $49.82 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe. What is Neovasc's official website? The official website for Neovasc is www.neovasc.com. How can I contact Neovasc? Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
